


The aim of the Fund is to achieve capital growth.
| Name | % Net Assets |
|---|---|
| Pfizer Inc. | 7.5% |
| Johnson & Johnson | 7.0% |
| Novartis AG | 5.7% |
| GlaxoSmithKline PLC | 5.6% |
| Roche Holding AG | 5.6% |
| Roche Holding AG | 4.0% |
| Merck & Co. Inc. | 3.8% |
| Amgen Inc. | 3.6% |
| Schering-Plough Corp. | 3.4% |
| AstraZeneca PLC | 3.0% |
| Key | % Net Assets |
|---|---|
| 7.5% | |
| 7.0% | |
| 5.7% | |
| 5.6% | |
| 74.2% |
| Date | n/a |
|---|---|
| Bid | 0.00 |
| Offer | 0.00 |
| Currency | n/a |
| Change | 0.00 |
| % | n/a |
| YTD change | 0.00 |
| YTD % | n/a |
| Fund Inception | 15/07/2002 |
|---|---|
| Fund Manager | Anne Marieke Ezendam |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | 500000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | -0.09 |
You are here: research